Hospital de Jerez-ko ikertzaileekin lankidetzan egindako argitalpenak (26)

2024

  1. Spanish Society of Medical Oncology recommendations for comprehensive assessment and care of cancer survivors’ needs

    Clinical and Translational Oncology

2022

  1. Relationship between nutritional treatment compliance and nutritional status improvements in patients with gastrointestinal impairment taking an oral peptide-based supplement

    Nutrition, Vol. 102

2021

  1. Lenalidomide and dexamethasone with or without clarithromycin in patients with multiple myeloma ineligible for autologous transplant: a randomized trial

    Blood Cancer Journal, Vol. 11, Núm. 5

2019

  1. Bendamustine as part of conditioning of autologous stem cell transplantation in patients with aggressive lymphoma: a phase 2 study from the GELTAMO group

    British Journal of Haematology, Vol. 184, Núm. 5, pp. 797-807

2018

  1. Radio-223 en la secuencia terapéutica del cáncer de próstata resistente a la castración metastásico

    Actas Urologicas Espanolas

2016

  1. Immune status of high-risk smoldering multiple myeloma patients and its therapeutic modulation under lendex: A longitudinal analysis

    Blood, Vol. 127, Núm. 9, pp. 1151-1162

2014

  1. Immunophenotypic alterations of bone marrow myeloid cell compartments in multiple myeloma patients predict for myelodysplasia-associated cytogenetic alterations

    Leukemia

2008

  1. A prospective PETHEMA study of tandem autologous transplantation versus autograft followed by reduced-intensity conditioning allogeneic transplantation in newly diagnosed multiple myeloma

    Blood, Vol. 112, Núm. 9, pp. 3591-3593

  2. R-ESHAP as salvage therapy for patients with relapsed or refractory diffuse large B-cell lymphoma: The influence of prior exposure to rituximab on outcome. A GEL/TAMO study

    Haematologica, Vol. 93, Núm. 12, pp. 1829-1836

2007

  1. Clinical outcome of patients with venous thromboembolism and renal insufficiency. Findings from the RIETE registry

    Thrombosis and Haemostasis, Vol. 98, Núm. 4, pp. 771-776

2006

  1. Reduced-intensity conditioning allogeneic transplantation is associated with a high incidence of extramedullary relapses in multiple myeloma patients [14]

    Leukemia

2005

  1. Allogeneic transplant with reduced intensity conditioning regimens may overcome the poor prognosis of B-cell chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy-chain gene and chromosomal abnormalities (11q- and 17p-)

    Clinical Cancer Research, Vol. 11, Núm. 21, pp. 7757-7763

  2. Influence of the intensity of the conditioning regimen on the characteristics of acute and chronic graft-versus-host disease after allogeneic transplantation

    British Journal of Haematology, Vol. 130, Núm. 3, pp. 394-403

2004

  1. Autologous stem-cell transplantation in diffuse large B-cell non-Hodgkin's lymphoma not achieving complete response after induction chemotherapy: The GEL/TAMO experience

    Annals of Oncology, Vol. 15, Núm. 10, pp. 1504-1509

2003

  1. Autologous stem cell transplantation for primary refractory Hodgkin's disease: Results and clinical variables affecting outcome

    Annals of Oncology, Vol. 14, Núm. 5, pp. 745-751

  2. High dose chemotherapy and autologous stem cell transplantation in patients with peripheral T-cell lymphoma not achieving complete response after induction chemotherapy. The GEL-TAMO experience

    Haematologica, Vol. 88, Núm. 12, pp. 1372-1377

  3. High-dose chemotherapy and autologous stem cell transplantation in peripheral T-cell lymphoma: The GEL-TAMO experience

    Annals of Oncology, Vol. 14, Núm. 12, pp. 1768-1775

  4. High-dose therapy in diffuse large cell lymphoma: Results and prognostic factors in 452 patients from the GEL-TAMO Spanish cooperative group

    Annals of Oncology, Vol. 14, Núm. 1, pp. 140-151

2002

  1. Low transplant-related mortality after second allogeneic peripheral blood stem cell transplant with reduced-intensity conditioning in adult patients who have failed a prior autologous transplant

    Bone Marrow Transplantation, Vol. 30, Núm. 2, pp. 63-68

  2. Nonmyeloablative transplantation with or without alemtuzumab: Comparison between 2 prospective studies in patients with lymphoproliferative disorders

    Blood, Vol. 100, Núm. 9, pp. 3121-3127